Get the Stockscreener App
11.53
1.54%
-0.18
After Hours:
11.53
Mink Therapeutics Inc stock is traded at $11.53, with a volume of 7,873.
It is down -1.54% in the last 24 hours and up +1.95% over the past month.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
See More
Previous Close:
$11.71
Open:
$11.9326
24h Volume:
7,873
Relative Volume:
0.29
Market Cap:
$54.12M
Revenue:
-
Net Income/Loss:
$-24.77M
P/E Ratio:
-15.79
EPS:
-0.73
Net Cash Flow:
$-17.36M
1W Performance:
-8.13%
1M Performance:
+1.95%
6M Performance:
+55.18%
1Y Performance:
+148.92%
1-Day Range:
$11.50
$11.93
1-Week Range:
$11.50
$12.82
52-Week Range:
$4.5601
$76.00
Mink Therapeutics Inc Stock (INKT) Company Profile
Name
Mink Therapeutics Inc
Sector
Industry
Phone
212-994-8250
Address
149 FIFTH AVENUE, NEW YORK
Compare INKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INKT
Mink Therapeutics Inc
|
11.53 | 54.97M | 0 | -24.77M | -17.36M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-14-25 | Downgrade | William Blair | Outperform → Mkt Perform |
Mink Therapeutics Inc Stock (INKT) Latest News
Trading Systems Reacting to (INKT) Volatility - news.stocktradersdaily.com
MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen - Defense World
Bond Watch: Is MiNK Therapeutics Inc. stock in correction or buying zoneJuly 2025 Update & Community Consensus Trade Signals - BỘ NỘI VỤ
Why MiNK Therapeutics Inc. stock is favored by top institutionsWeekly Trading Summary & Community Verified Trade Signals - Newser
How Mink Therapeutics Inc. (INKT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Is MiNK Therapeutics Inc. (6Q40) stock inflation resilientQuarterly Profit Report & Daily Growth Stock Tips - Newser
What downside risks could hit MiNK Therapeutics Inc. (6Q40) stockJuly 2025 Snapshot & AI Enhanced Market Trend Forecasts - Newser
MiNK Therapeutics (INKT) Stock Analysis Report | Financials & Insights - Benzinga
Why MiNK Therapeutics Inc. (6Q40) stock appeals to dividend investorsQuarterly Trade Summary & Growth Focused Entry Point Reports - Newser
Will MiNK Therapeutics Inc. (6Q40) stock recover faster than industryStock Surge & Momentum Based Trading Signals - Newser
How MiNK Therapeutics Inc. (6Q40) stock compares with tech leaders2025 Trading Volume Trends & High Accuracy Swing Entry Alerts - Newser
Published on: 2025-12-02 06:12:45 - Newser
Will MiNK Therapeutics Inc. (6Q40) stock outperform value peersMarket Activity Recap & Target Return Focused Stock Picks - Newser
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of “Hold” from Brokerages - Defense World
Why MiNK Therapeutics Inc. stock is seen as undervaluedEarnings Recap Report & Real-Time Volume Surge Alerts - moha.gov.vn
Buybacks Report: Why MiNK Therapeutics Inc. stock attracts global investorsM&A Rumor & Risk Managed Investment Signals - BỘ NỘI VỤ
(INKT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
MiNK Therapeutics Inc 6Q40 Stock Analysis and ForecastBull Market Opportunities & Learn From the Strategies of Institutions - earlytimes.in
MiNK Therapeutics Inc Stock Analysis and ForecastSupport Level Holds & Small Capital Trading Plans - earlytimes.in
MiNK Therapeutics announces publication of new preclinical data for MiNK-215 - MSN
How reliable is MiNK Therapeutics Inc. (6Q40) stock dividend growthEarnings Summary Report & Free Safe Capital Growth Stock Tips - newser.com
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors - The Manila Times
MiNK Therapeutics Advances iNKT Platform in Q3 2025 - MSN
MiNK Therapeutics Announces New Data Showing MiNK-215 - GlobeNewswire
MiNK Therapeutics (NASDAQ: INKT) unveils MiNK-215 CAR-iNKT for solid tumors - Stock Titan
Why global investors buy MiNK Therapeutics Inc. (6Q40) stock - newser.com
How MiNK Therapeutics Inc. stock performs in rate cut cyclesBond Market & Community Shared Stock Ideas - newser.com
Mink Therapeutics Shares Slide After Announcing $50 Million Stock Offering - MSN
FY2025 EPS Estimate for MiNK Therapeutics Raised by Analyst - Defense World
Will MiNK Therapeutics Inc. stock see insider buyingJuly 2025 Sector Moves & Risk Managed Trade Strategies - newser.com
What’s next for MiNK Therapeutics Inc. stock priceBond Market & Verified Momentum Stock Watchlist - newser.com
Published on: 2025-11-19 15:48:22 - newser.com
Using fundamentals and technicals on MiNK Therapeutics Inc.2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Why analysts remain bullish on MiNK Therapeutics Inc. stockJuly 2025 Price Swings & Consistent Growth Equity Picks - newser.com
Is MiNK Therapeutics Inc. stock safe for conservative investors2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
Can MiNK Therapeutics Inc. stock resist sector downturnsTrade Volume Summary & Entry Point Strategy Guides - newser.com
Mink Therapeutics Inc Stock (INKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):